KONGRES UDRUŽENJA
ZA HRONIČNE CREVNE
INFLAMATORNE BOLESTI SRBIJE

SIBDA 2026

Hotel Mona Plaza
Beograd, 6–8. novembar 2026.



FINALNI PROGRAM

FINAL PROGRAMME



Poštovane koleginice i kolege, dragi prijatelji,

Veliko mi je zadovoljstvo da vas, u ime Udruženja za hronične crevne inflamatorne bolesti Srbije (SIBDA), pozovem na naš Kongres koji će se održati od 6. do 8. novembra 2026. godine u Beogradu.

Kongres će okupiti stručnjake iz Srbije, regiona i inostranstva sa zajedničkim ciljem da razmenimo znanja i iskustva i razgovaramo o najvažnijim pitanjima savremene dijagnostike, praćenja i lečenja inflamatornih bolesti creva. Posebno nam je važno da naučna saznanja povežemo sa svakodnevnom kliničkom praksom i izazovima sa kojima se susrećemo u radu sa pacijentima.

Program obuhvata širok spektar tema – od epidemiologije, mikrobioma i dijagnostike, preko pedijatrijskog IBD-a i savremenih terapijskih pristupa, do multidisciplinarnog lečenja, hirurgije i posebnih kliničkih situacija. Pored predavanja renomiranih stručnjaka, značajan prostor biće posvećen diskusiji, razmeni iskustava i različitim pristupima u donošenju terapijskih odluka.

Posebnu vrednost Kongresu daje i uključivanje različitih članova IBD tima, kao i perspektive samih pacijenata. Verujemo da upravo takav pristup doprinosi boljem razumevanju bolesti i kvalitetnijoj brizi o pacijentima.


Želja nam je da ovaj Kongres bude mesto susreta, novih ideja i otvorenog stručnog dijaloga, ali i prilika da dodatno povežemo IBD zajednicu u Srbiji i regionu.

Pored bogatog naučnog programa, predviđen je i zanimljiv društveni program, koji će pružiti dodatnu priliku za druženje, razmenu iskustava i povezivanje kolega u prijatnoj atmosferi.

Radujem se našem susretu u Beogradu!

Srdačno,

Prof. dr Dino Tarabar
Predsednik Udruženja za hronične crevne inflamatorne bolesti Srbije



Dear Colleagues and Friends,

It is my great pleasure to invite you, on behalf of the Serbian IBD Association (SIBDA), to our Congress, which will be held from 6 to 8 November 2026 in Belgrade.

The Congress will bring together experts from Serbia, the region and abroad, with the shared aim of exchanging knowledge and experience and of discussing the key questions of contemporary diagnosis, monitoring and treatment of inflammatory bowel disease. It is particularly important to us that scientific findings be connected with everyday clinical practice and with the challenges we meet in our work with patients.

The programme covers a broad spectrum of topics – from epidemiology, the microbiome and diagnostics, through paediatric IBD and contemporary therapeutic approaches, to multidisciplinary treatment, surgery and specific clinical situations. In addition to lectures by distinguished experts, considerable space will be devoted to discussion, to the exchange of experience and to differing approaches in therapeutic decision-making.

Particular value is lent to the Congress by the involvement of the various members of the IBD team, as well as by the perspectives of patients themselves. We believe that such an approach contributes to a better understanding of the disease and to higher-quality patient care.

It is our wish that this Congress should be a place of encounter, of new ideas and of open professional dialogue, and an opportunity to connect the IBD community in Serbia and the region further.

Alongside a rich scientific programme, an engaging social programme has been envisaged, offering a further opportunity for socialising, for the exchange of experience and for bringing colleagues together in a pleasant atmosphere.

I look forward to our meeting in Belgrade!

Yours sincerely,

Prof. dr Dino Tarabar
President of the Serbian IBD Association




NAUČNI I ORGANIZACIONI ODBOR
SCIENTIFIC AND ORGANIZING COMMITTEE

NAUČNI ODBOR / SCIENTIFIC COMMITTEE

Prof. dr Nataša Zdravković
Prof. dr Dragana Mijač
Doc. dr Stanko Petrović

ORGANIZACIONI ODBOR / ORGANIZING COMMITTEE

Prof. dr Dino Tarabar
Prof. dr Aleksandra Sokić Milutinović
Doc. dr Mirjana Stojšić
Dr Olgica Latinović-Bošnjak
Dr Zoran Milenković



OPŠTE INFORMACIJE

MESTO ODRŽAVANJA

Hotel Mona Plaza Beograd
Cara Dušana 62–64
11 000 Beograd
tel: 011 4024 670

KOTIZACIJA

Kotizacija za učešće na kongresu iznosi 200,00 EUR.
Na navedeni iznos obračunava se PDV po stopi od 20%.
Za sve dodatne informacije možete se obratiti
tehničkom organizatoru putem mejla:
sibda@miross.rs

REGISTRACIJA

Registraciju i uplatu kotizacije možete izvršiti putem sledećeg formulara:
REGISTRACIJA / REGISTRATION

SMEŠTAJ

Hotel Mona Plaza Beograd
Cara Dušana 62–64
11 000 Beograd

AKREDITACIJA

Postupak akreditacije Kongresa kod Zdravstvenog saveta Srbije je u toku.



GENERAL INFORMATION

VENUE

Hotel Mona Plaza Belgrade
Cara Dušana 62–64
11 000 Belgrade
tel: +381 11 4024 670

REGISTRATION FEE

The registration fee for the Congress amounts to EUR 200.00.
VAT at the rate of 20% is applied to the stated amount.
For any further information, please contact
the technical organiser by e-mail:
sibda@miross.rs

REGISTRATION


Registration and payment of the fee may be completed via the following form:
REGISTRATION

ACCOMMODATION

Hotel Mona Plaza Belgrade
Cara Dušana 62–64
11 000 Belgrade

ACCREDITATION

The accreditation of the Congress by the Health Council of Serbia is in progress.



UPUTSTVO ZA PRIPREMU SAŽETAKA

Rok za slanje sažetaka 15.10.2026

Sažetke poslati emailom na sibda@miross.rs

Prilikom pripreme i dostavljanja apstrakata, molimo da se poštuju sledeća pravila, kako bi svi radovi bili pripremljeni u jedinstvenom formatu i odgovarajućem naučnom standardu.

Razmatraće se sledeće vrste apstrakata: originalni naučni radovi (original research), prikazi slučaja (case reports) i apstrakti sa prikazom dizajna studije (study design abstracts). Prikazi slučaja i apstrakti sa prikazom dizajna studije mogu se podneti ukoliko se mogu strukturisati u četiri obavezne sekcije: uvod-metodologija-rezultati-zaključak, uz poštovanje svih ostalih zahteva za podnošenje apstrakta.

1. Opšte informacije

1.1. Apstrakti se dostavljaju na srpskom ili engleskom jeziku. Apstrakt se dostavlja kao Microsoft Word dokument.

1.2. Maksimalna dužina apstrakta iznosi 2.750 karaktera sa razmacima. U navedeni limit ne uračunavaju se: naslov apstrakta, imena autora, afilijacije, reference.

1.3. Format dokumenta: preporučeni format: font: arial; veličina osnovnog teksta: 11 pt; naslov: 14 pt, bold; naslovi sekcija: 11 pt, bold; autori: 11 pt; afilijacije: 11 pt; prored: 1,0 (single spacing); razmak pre pasusa: 0 pt; razmak posle pasusa: 0 pt; poravnanje: levo; ne koristiti: obostrano poravnanje (Justify); ne koristiti: uvlačenje prvog reda; ne koristiti: nepotrebne prazne redove između pasusa; margine: 2,5 cm sa svih strana.

1.4. Naslov: kratak, jasan i informativan. Imena autora ne navode se u naslovu. Pisanje naslova: naslov se piše malim slovima, uz veliko početno slovo prve reči naslova i prve reči nakon dve tačke, kao i velika slova za akronime i vlastita imena.

1.5. Autori i afilijacije: ime i prezime autora, pun naziv ustanove/institucije, grad, državu, odgovarajuću afilijaciju. Akademske i profesionalne titule (MD, PhD, Prof.) ne navode se uz imena autora.

1.6. Oblast/tema apstrakta: navesti jednu oblast koja najbolje opisuje glavni fokus rada. Dostupne oblasti su: bazična nauka (laboratorijska i eksperimentalna istraživanja); klinička istraživanja: dijagnoza i ishodi; klinička istraživanja: terapija i praćenje; epidemiologija; genetika; mikrobiologija; apstrakti medicinskih sestara.



2. Struktura apstrakta

Apstrakt treba da bude strukturisan u četiri obavezne celine: uvod – kratko predstaviti problem, značaj teme i cilj istraživanja; metodologija – navesti dizajn istraživanja; rezultati – prikazati najvažnije rezultate istraživanja; zaključak – jasno navesti glavnu poruku i zaključak koji proizlazi iz rezultata. Ova struktura primenjuje se na: originalne naučne radove, prikaze slučaja, apstrakte sa prikazom dizajna studije.

3. Tehnički i sadržajni zahtevi:

3.1. Skraćenice: standardne medicinske skraćenice mogu se koristiti. Nestandardne skraćenice potrebno je pri prvom navođenju napisati punim nazivom, nakon čega se skraćenica može koristiti u tekstu.

3.2. Lekovi i proizvodi: lekove treba navoditi prema generičkom nazivu, malim slovima. Komercijalni/trgovački nazivi lekova ne treba da se koriste u naslovu ili tekstu apstrakta.

3.3. Grafički prikazi, slike i tabele: apstrakt može sadržati najviše 2 grafička prikaza, slike ili tabele. Tehnički zahtevi: format: JPG ili PNG; maksimalna veličina pojedinačne slike: 1,5 MB; maksimalne dimenzije: 800 × 800 px; rezolucija: najmanje 300 dpi. Tabele se dodaju kao slika. Naslov/legenda i fusnote za slike i tabele treba da budu uključeni u samu sliku.

3.4. Reference: reference nisu obavezne, osim ukoliko su relevantne za sadržaj apstrakta. Ukoliko se koriste: preporučuje se AMA stil, dozvoljeno je najviše 4 reference, reference se ne uračunavaju u ograničenje od 2.750 karaktera.

3.5. Ključne reči: uz apstrakt je potrebno navesti 3–5 ključnih reči (Keywords).


4. Etički i drugi zahtevi:

4.1. Originalnost i odgovornost autora: Autor koji podnosi apstrakt odgovoran je za: tačnost naučnog sadržaja; tačnost svih prikazanih podataka; poštovanje etičkih standarda; pribavljanje potrebnih etičkih saglasnosti, dozvola i drugih odobrenja, kada su potrebna. Svi koautori moraju biti upoznati sa sadržajem apstrakta i saglasni sa njegovim podnošenjem.

4.2. Prethodno objavljivanje i prezentacija: apstrakt ne sme biti prethodno objavljen niti prethodno prezentovan na međunarodnom kongresu, niti sme biti prethodno objavljen kao rad u časopisu. Isti apstrakt ne može biti istovremeno podnet više puta od strane različitih koautora.

4.3. Konflikt interesa: za sve autore potrebno je navesti relevantne podatke o postojanju ili nepostojanju konflikta interesa (Conflict of Interest).

4.4. Upotreba veštačke inteligencije: veštačka inteligencija ne sme biti korišćena za kreiranje, menjanje ili manipulaciju originalnim naučnim podacima i rezultatima istraživanja. Ukoliko je AI tehnologija korišćena u pripremi apstrakta, njena upotreba mora biti deklarisana.



INSTRUCTIONS FOR ABSTRACT PREPARATION

Abstract submission deadline 15.10.2026

Abstract should be submitted exclusively on email sibda@miross.rs

When preparing and submitting abstracts, please adhere to the following rules to ensure that all submissions are prepared in a uniform format and meet the appropriate scientific standards.

The following types of abstracts will be considered: original research, case reports, and study design abstracts. Case reports and study design abstracts may be submitted provided they can be structured into four mandatory sections: introduction-methodology-results-conclusion, while complying with all other abstract submission requirements.

1. General Information

1.1. Language and File Format

Abstracts may be submitted in either Serbian or English. The abstract must be submitted as a Microsoft Word document.

1.2. Length Limitations

The maximum length of the abstract is 2,750 characters, including spaces. The following elements are excluded from this limit: abstract title, author names, affiliations, and references.

1.3. Document Formatting

- Recommended Font: Arial.
- Body Text Size: 11 pt.
- Title: 14 pt, bold.
- Section Headers: 11 pt, bold.
- Authors & Affiliations: 11 pt.
- Line Spacing: 1.0 (single spacing).
- Paragraph Spacing: 0 pt before, 0 pt after.
- Alignment: Left-aligned. Do not use Justified alignment.
- Indentation: Do not use first-line indentation.
- Spacing between paragraphs: Do not use unnecessary blank lines between paragraphs.
- Margins: 2.5 cm on all sides.



1.4. Title

The title must be short, clear, and informative. Author names should not be included in the title.

- Title Case: The title should be written in lowercase letters, with a capital letter only for the first word of the title, the first word following a colon, acronyms, and proper nouns.

1.5. Authors and Affiliations

Provide the first and last name of the authors, the full name of the institution/organization, city, country, and the corresponding affiliation. Academic and professional titles (e.g., MD, PhD, Prof.) should not be listed alongside author names.

1.6. Abstract Category/Topic

Select one category that best describes the main focus of the work. Available categories include:

- Basic science (laboratory and experimental research)
- Clinical research: Diagnosis and outcomes
- Clinical research: Therapy and monitoring
- Epidemiology
- Genetics
- Microbiology
- Nursing abstracts

2. Abstract Structure

The abstract must be structured into four mandatory sections:

- Introduction: Briefly present the problem, the significance of the topic, and the aim of the research.
- Methodology: State the research design.
- Results: Present the most important research findings.
- Conclusion: Clearly state the main message and conclusion derived from the results.

This structure applies universally to original research, case reports, and study design abstracts.


3. Technical and Content Requirements

3.1. Abbreviations

Standard medical abbreviations may be used. Non-standard abbreviations must be spelled out in full upon first mention, after which the abbreviation may be used throughout the text.

3.2. Drugs and Products

Drugs must be referred to by their generic name, in lowercase letters. Commercial/brand names of drugs should not be used in the title or body of the abstract.



3.3. Graphical Elements, Images, and Tables

An abstract may contain a maximum of 2 graphical elements, images, or tables.

- Technical Requirements: Format: JPG or PNG; maximum file size per individual image: 1.5 MB; maximum dimensions: 800 × 800 px; resolution: at least 300 dpi.
- Tables must be added as images.
- The title/legend and footnotes for images and tables must be embedded within the image itself.

3.4. References

References are not mandatory unless they are highly relevant to the abstract content. If used:

- The AMA citation style is recommended.
- A maximum of 4 references is allowed.
- References do not count toward the 2,750-character limit.

3.5. Keywords

A total of 3–5 keywords must be provided alongside the abstract.

4. Ethical and Other Requirements

4.1. Originality and Author Responsibility

The submitting author is responsible for: the accuracy of the scientific content; the accuracy of all presented data; compliance with ethical standards; and obtaining necessary ethical approvals, consents, and other permissions when required. All co-authors must be familiar with the abstract content and agree to its submission.

4.2. Prior Publication and Presentation

The abstract must not have been previously published or presented at an international congress, nor should it have been previously published as a full journal paper. The same abstract cannot be submitted multiple times simultaneously by different co-authors.

4.3. Conflict of Interest

Relevant information regarding the presence or absence of a Conflict of Interest must be disclosed for all authors.


4.4. Use of Artificial Intelligence

Artificial intelligence must not be used to create, alter, or manipulate original scientific data and research results. If AI technology was utilized in the preparation of the abstract, its use must be declared.



FINALNI PROGRAM / FINAL PROGRAMME

	PETAK, 06. NOVEMBAR 2026. / FRIDAY, NOVEMBER 6, 2026
14.30-15.15	Registracija / Registration
15.15-15.30	Svečano otvaranje / Opening Ceremony
15.30-17.00	**Sesija I: Kako prepoznati bolest i kako je najbolje lečiti / Session I: How to Recognize the Disease and How to Best Treat It** Moderatori: Prof. dr Miodrag Krstić, Dr Olgica Latinović-Bošnjak
15.30-15.50	Epidemiologija u IBD. Kakav je trend u svetu i u regionu / Epidemiology in IBD: What is the Trend Globally and Regionally **Prof. dr David Drobne**, Univerzitetni klinični center Ljubljana, Slovenija / University Medical Centre Ljubljana, Slovenia
15.50-16.05	Značaj mikrobioma u IBD / The Importance of Microbiome in IBD **Prof. dr Mirjana Rajlić-Stojanović**, Tehnološko-metalurški fakultet, Univerzitet u Beogradu, Srbija / Faculty of Technology and Metallurgy, University of Belgrade, Serbia
16.05-16.20	Konvencionalna terapija i kako je optimizovati / Conventional Therapy and How to Optimize It **Prof. dr Mirela Bašić Denjagić**, Univerzitetski klinički centar Tuzla, Bosna i Hercegovina / University Clinical Center Tuzla, Bosnia and Herzegovina
16.20-16.40	Kada i kako izabrati adekvatnu kombinovanu terapiju u IBD / When and How to Choose Adequate Combination Therapy in IBD **Prof. dr Walter Reinisch**, Medicinski univerzitet u Beču, Austrija / Medical University of Vienna, Austria
16.40-17.00	Diskusija / Discussion
17.00-17.30	**Satelitski simpozijum / Satellite Symposium MEDICA LINEA-AbbVie**
	Upadacitinib – fleksibilna terapijska opcija u IBD / Upadacitinib – Flexible Treatment Option in IBD **Prof. dr Walter Reinisch**, Medicinski univerzitet u Beču, Austrija / Medical University of Vienna, Austria




17.30-18.45	**Sesija II: Napredak u dijagnostici i monitoringu bolesti / Session II: Advances in Diagnostics and Disease Monitoring**
	Moderatori: Prof. dr Aleksandra Pavlović Marković, Dr Dragan Vasin
17.30-17.45	Značaj endoskopije u IBD / The Importance of Endoscopy in IBD **Prof. dr Srđan Đuranović**, Univerzitetski klinički centar Srbije, Beograd, Srbija / University Clinical Center of Serbia, Belgrade, Serbia
17.45-18.00	Intestinalni UZ u IBD / Intestinal Ultrasound in IBD **Dr Žarko Krnetić**, Univerzitetski klinički centar Vojvodine, Novi Sad, Srbija / University Clinical Center of Vojvodina, Novi Sad, Serbia
18.00-18.15	Vizualizacione tehnike u IBD / Imaging Techniques in IBD **Dr Miodrag Lalošević**, KBC „Dr Dragiša Mišović – Dedinje", Beograd, Srbija / University Hospital Center "Dr. Dragiša Mišović – Dedinje", Belgrade, Serbia
18.15-18.30	Značaj inflamatornih biomarkera u dijagnostici i praćenju IBD / The Importance of Inflammatory Biomarkers in Diagnostics and Monitoring of IBD **Dr Tamara Knežević Ivanovski**, Kliničko-bolnički centar „Zvezdara", Beograd, Srbija / University Hospital Center "Zvezdara", Belgrade, Serbia
18.30-18.45	Diskusija / Discussion
20.30-00.00	Društveni program / Social Programme

	SUBOTA, 07. NOVEMBAR 2026. / SATURDAY, NOVEMBER 7, 2026
08.30-09.55	**Sesija III: Pedijatrijski IBD / Session III: Pediatric IBD**
	Moderatori: Prof. dr Aleksandra Sokić Milutinović, Doc. dr Mirjana Stojšić
08.30-08.45	Terapija i monitoring tokom trudnoće / Therapy and Monitoring During Pregnancy **Prof. dr Aleksandra Sokić Milutinović**, Univerzitetski klinički centar Srbije / Medicinski fakultet, Univerzitet u Beogradu, Srbija / University Clinical Center of Serbia / Faculty of Medicine, University of Belgrade, Serbia
08.45-09.00	Koliko rano mislimo na IBD / How Early Do We Think of IBD **Doc. dr Mirjana Stojšić**, Institut za zdravstvenu zaštitu dece i omladine Vojvodine, Novi Sad, Srbija / Institute for Children and Youth Health Care of Vojvodina, Novi Sad, Serbia
09.00-09.20	Novi terapijski horizonti u PIBD: Između želja i mogućnosti / New Therapeutic Horizons in PIBD: Between Wishes and Possibilities **Prof. dr Marla Dubinsky**, Mount Sinai Kravis Children's Hospital, Njujork, SAD / Mount Sinai Kravis Children's Hospital, New York, USA




09.20-09.40	Tranzicija iz pedijatrijskog u adultni IBD centar / Transition from Pediatric to Adult IBD Center **Dr Nina Ristić**, Univerzitetska dečja klinika Tiršova, Beograd, Srbija / University Children's Hospital Tiršova, Belgrade, Serbia **Dr Ivana Kitić**, Institut za zdravstvenu zaštitu majke i deteta „Dr Vukan Čupić", Beograd, Srbija / Mother and Child Health Care Institute of Serbia "Dr. Vukan Čupić", Belgrade, Serbia
09.40-09.55	Diskusija / Discussion
09.55-11.30	**Sesija IV: Savremeni pristup u lečenju IBD pacijenata (1. deo) / Session IV: Modern Approach in the Treatment of IBD Patients (Part 1)** Moderatori: Prof. dr Dino Tarabar, Doc. dr Vedran Tomašić
09.55-10.15	Treat to target: Šta smo naučili, a šta nam donosi STRIDE 3 / Treat to Target: What Have We Learned and What Does STRIDE 3 Bring Us **Prof. dr Marc Ferrante**, KU Leuven, Leuven, Belgija / KU Leuven, Leuven, Belgium
10.15-10.35	Nove preporuke u lečenju ulceroznog kolitisa / New Recommendations in the Treatment of Ulcerative Colitis **Doc. dr Vedran Tomašić**, Klinički bolnički centar „Sestre milosrdnice", Zagreb, Hrvatska / University Hospital Center "Sestre milosrdnice", Zagreb, Croatia
10.35-10.55	Nove preporuke u lečenju Mb. Crohn / New Recommendations in the Treatment of Crohn's Disease **Prim. dr Vladimir Borzan**, Osijek, Hrvatska / Osijek, Croatia
10.55-11.15	Refrakterni IBD pacijent: Šta i kako dalje? / Refractory IBD Patient: What Next and How? **Prof. dr Cory Siegel**, Dartmouth-Hitchcock Medical Center, Libanon, SAD / Dartmouth-Hitchcock Medical Center, Lebanon, USA
11.15-11.30	Diskusija / Discussion
11.30–12.00	Satelitski simpozijum / Satellite Symposium JOHNSON&JOHNSON Mesto inhibitora IL-23 u lečenju inflamatornih bolesti creva / The Role of IL-23 Inhibitors in the Treatment of Inflammatory Bowel Disease **Prof. dr Marc Ferrante**, KU Leuven, Leuven, Belgija / KU Leuven, Leuven, Belgium
12.00-12.20	Kafe pauza / Coffee Break



12.20-13.50	**Sesija V: Savremeni pristup u lečenju IBD pacijenata (2. deo)** **Session V: Modern Approach in the Treatment of IBD Patients (Part 2)** Moderatori: Prof. dr David Drobne, Dr Mirjana Cvetković
12.20-12.35	Kako na vreme prepoznati pacijenta za biološku terapiju / How to Timely Identify a Patient for Biologic Therapy **Dr Olgica Latinović-Bošnjak**, Univerzitetski klinički centar Vojvodine (UKCV), Novi Sad, Srbija / University Clinical Center of Vojvodina (UKCV), Novi Sad, Serbia
12.35-12.55	Optimizovati terapiju ili promeniti terapijsku klasu / Optimize Therapy or Change Therapeutic Class **Prof. dr David Rubin**, University of Chicago Medicine, Čikago, SAD / University of Chicago Medicine, Chicago, USA
12.55-13.15	Kako postići najbolje rezultate sa naprednom terapijom / How to Achieve the Best Results with Advanced Therapy **Prof. dr Dino Tarabar**, KBC „Dr Dragiša Mišović – Dedinje", Beograd, Srbija / University Hospital Center "Dr. Dragiša Mišović - Dedinje", Belgrade, Serbia
13.15-13.35	Da li i kako lečiti asimptomatsku Crohn-ovu bolest / Whether and How to Treat Asymptomatic Crohn's Disease **Dr Jurij Hanzel**, Univerzitetni klinični center Ljubljana, Slovenija / University Medical Centre Ljubljana, Slovenia
13.35-13.50	Diskusija / Discussion
14.00-15.00	Ručak i Poster sesija / Lunch and Poster Session
15.00-16.30	**Sesija VI: Multidisciplinarni pristup u lečenju IBD** **Session VI: Multidisciplinary Approach in the Treatment of IBD** Moderatori: Dr Ivana Jovičić, Doc. dr Dušan Popović
15.00-15.20	Kad i kako nam može pomoći reumatolog u lečenju IBD / When and How a Rheumatologist Can Help Us in the Treatment of IBD **Dr Mirjana Cvetković**, Kliničko-bolnički centar „Bežanijska kosa", Beograd, Srbija / University Hospital Center "Bežanijska kosa", Belgrade, Serbia **Prof. dr Sonja Stojanović**, Institut „Niška Banja", Niš, Srbija / Institute "Niška Banja", Niš, Serbia
15.20-15.40	Kožne promene koje viđamo u IBD / Skin Manifestations Seen in IBD **Prof. dr Vesna Brzački**, Univerzitetski klinički centar Niš, Srbija / University Clinical Center Niš, Serbia **Prof. dr Lidija Kandolf**, Vojnomedicinska akademija, Beograd, Srbija / Military Medical Academy, Belgrade, Serbia




15.40-15.55	Primarni sklerozirajući holangitis i IBD / Primary Sclerosing Cholangitis and IBD **Prof. dr Đorđe Ćulafić**, Univerzitetski klinički centar Srbije, Beograd, Srbija / University Clinical Center of Serbia, Belgrade, Serbia
15.55-16.15	Mentalno zdravlje i IBD / Mental Health and IBD **Dr Dunja Jakšić**, Kliničko-bolnički centar „Zemun", Beograd, Srbija / University Hospital Center Zemun, Belgrade, Serbia **Prof. dr Milan Latas**, Univerzitetski klinički centar Srbije, Beograd, Srbija / University Clinical Center of Serbia, Belgrade, Serbia
16.15-16.30	Diskusija / Discussion
16.30-17.00	**Satelitski simpozijum / Satellite Symposium TAKEDA** **VERDICT: rezultati u znaku Entyvia / VERDICT: Results Marked by Entyvio**
17.00-18.45	**Sesija VII: Mesto i značaj hirurgije u IBD /** **Session VII: The Role and Importance of Surgery in IBD** Moderatori: Prof. dr Srđan Đuranović, Prof. dr Miljan Ćeranić
17.00-17.20	Kad je hirurgija prva terapijska opcija i zašto? / When is Surgery the First Therapeutic Option and Why? **Prof. dr Đorđi Deriban** , Univerzitetna klinika za gastroenterohepatologija, Skoplje, Severna Makedonija / University Clinic for Gastroenterohepatology, Skopje, North Macedonia
17.20-17.40	Treat to target u perianalnoj bolesti / Treat to Target in Perianal Disease **Prof. dr Iris Dotan** , Rabin Medical Center, Petah Tikva, Izrael / Rabin Medical Center, Petah Tikva, Israel
17.40-17.55	Hirurške procedure u IBD / Surgical Procedures in IBD **Prof. dr Miljan Ćeranić** , Centar za minimalno-invazivnu hirurgiju, Univerzitetski klinički centar Srbije, Beograd, Srbija / Center for Minimal Invasive Surgery, University Clinical Center of Serbia, Belgrade, Serbia
17.55-18.10	Endoskopske/terapijske procedure u IBD / Endoscopic/Therapeutic Procedures in IBD **Doc. dr Nikola Panić**, KBC „Dr Dragiša Mišović – Dedinje", Beograd, Srbija / University Hospital Center "Dr. Dragiša Mišović – Dedinje", Belgrade, Serbia
18.10-18.30	Postoperativna prevencija bolesti: Šta je novo? / Postoperative Disease Prevention: What's New? **Doc. dr Aida Saray**, Klinički centar Univerziteta u Sarajevu (KCUS), Bosna i Hercegovina / Clinical Center of the University of Sarajevo (KCUS), Bosnia and Herzegovina
18.30-18.45	Diskusija / Discussion
20.30	Svečana večera / Gala Dinner



	NEDELJA, 08. NOVEMBAR 2026. / SUNDAY, NOVEMBER 8, 2026
09.00-10.30	**Sesija VIII: Posebne situacije u lečenju IBD** **Session VIII: Special Situations in the Treatment of IBD** Moderatori: Prof. dr Goran Hauser, Dr Aleksandra Pavlović
09.00-09.20	Mesto i značaj nutritivne terapije: prva linija ili je još rano? / The Role and Importance of Nutritional Therapy: First Line or is it Too Early? **Prof. dr Iva Hojsak**, Klinika za dječje bolesti Zagreb, Hrvatska / Children's Hospital Zagreb, Croatia
09.20-09.40	Ima li mesta fekalnoj transplantaciji u IBD? / Is There a Place for Fecal Microbiota Transplantation in IBD? **Prof. dr Goran Hauser**, Klinički bolnički centar Rijeka, Hrvatska / University Hospital Center Rijeka, Croatia
09.40-09.55	Dilema: mikroskopski kolitis ili IBD, kako je rešiti? / Dilemma: Microscopic Colitis or IBD, How to Resolve It? **Prof. dr Biljana Radovanović Dinić**, Univerzitetski klinički centar Niš, Srbija / University Clinical Center Niš, Serbia
09.55-10.15	Lečenje IBD pacijenata sa simptomima sličnim IBS / Treatment of IBS-like Symptoms in IBD Patients **Dr Tatiana Jocić**, Univerzitetski klinički centar Vojvodine, Novi Sad, Srbija / University Clinical Center of Vojvodina, Novi Sad, Serbia
10.15-10.30	Diskusija / Discussion
10.30-11.15	**Sesija IX: Pogled iz ugla pacijenata / Session IX: Patient Perspective** Moderator: Olivera Ćulibrk
10.30-10.45	Željko Gardlo, Hrvatska (Udruženje HUCUK) / Croatia (HUCUK Association)
10.45-11.00	Mateja Saje, Slovenija (Društvo KVČB) / Slovenia (KVČB Society)
11.00-11.15	Olivera Ćulibrk, Srbija (Udruženje UKUKS) / Serbia (UKUKS Association)
11.15-12.35	**Sesija X: Važne informacije za kraj / Session X: Closing Essential Insights** Moderatori: Prof. dr Brigita Smolović, Dr Zoran Milenković
11.15-11.30	Najznačajniji članci iz IBD u 2026. / Most Significant Articles in IBD in 2026 **Dr Zoran Milenković**, KBC „Dr Dragiša Mišović – Dedinje", Beograd, Srbija / University Hospital Center "Dr. Dragiša Mišović – Dedinje", Belgrade, Serbia
11.30-11.45	Savremena terapija pouchitisa / Modern Treatment of Pouchitis **Doc. dr Stanko Petrović**, Vojnomedicinska akademija, Beograd, Srbija / Military Medical Academy, Belgrade, Serbia



11.45-12.05	Infekcije u IBD: Kako ih sprečiti i lečiti / Infections in IBD: How to Prevent and Treat Them **Prof. dr Brigita Smolović**, Klinički centar Crne Gore, Podgorica, Crna Gora / Clinical Center of Montenegro, Podgorica, Montenegro
12.05-12.20	Maligniteti u IBD / Malignancies in IBD **Prof. dr Nataša Zdravković**, Univerzitetski klinički centar Kragujevac, Srbija / University Clinical Center Kragujevac, Serbia
12.20-12.35	Diskusija / Discussion
12.35-13.00	Najbolji apstrakti i Zatvaranje kongresa / Best Abstracts & Closing Ceremony
13.00-14.00	Ručak / Lunch



POSTER SESIJA / POSTER SESSION

1. **Karakteristike mineralne gustine kostiju kod dece sa inflamatornim bolestima creva**
   Milica Kovačević, Mirjana Stojšić, Nina Brkić, Nikola Stojšić, Marko Rajković, Ognjen Ležakov, Savina Marković
2. **Crohn's disease presenting with acute gastrointestinal bleeding: A case report**
   Boško Nikolić, Dušan Radojević, Vojislav Đukić, Mladen Maksić, Jelena Živić, Nataša Zdravković
3. **Association between concomitant immunomodulatory therapy and immunogenicity of anti-TNF-α biologics in patients with inflammatory bowel disease**
   Jelena Živić, Miloš Živić, Dušan Radojević, Vojislav Đukić, Mladen Maksić, Boško Nikolić, Nataša Zdravković
4. **Correlation between Crohn's disease activity and periodontitis severity**
   Miloš Živić, Jelena Živić, Dušan Radojević, Vojislav Đukić, Mladen Maksić, Boško Nikolić, Nataša Zdravković
5. **Platelet aggregability as an indicator of clinical and endoscopic activity in ulcerative colitis**
   Mladen Maksić, Dušan Radojević, Vojislav Đukić, Jelena Živić, Boško Nikolić, Saša Perić, Tijana Maksić, Mateja Zdravković, Zeljko Todorović, Miloš Živić, Nataša Zdravković
6. **Ulcerative Colitis and Atherosclerosis: Inflammatory, Lipid, and Hemostatic Profile of Cardiovascular Risk**
   Vojislav Đukić, Dušan Radojević, Mladen Maksić, Jelena Živić, Boško Nikolić, Tijana Maksić, Mateja Zdravković, Zeljko Todorović, Miloš Živić, Nataša Zdravković
7. **Ulcerative colitis and pancreatic serous cystadenoma: A case report**
   Boško Nikolić, Dušan Radojević, Vojislav Đukić, Mladen Maksić, Jelena Živić, Nataša Zdravković
8. **Dynamic changes in natriuretic peptides following therapy escalation in moderate-to-severe ulcerative colitis**
   Dušan Radojević, Mladen Maksić, Vojislav Đukić, Jelena Živić, Boško Nikolić, Mirjana Cvetković, Tijana Maksić, Mateja Zdravković, Zeljko Todorović, Miloš Živić, Nataša Zdravković
9. **Immunomodulatory therapy, therapeutic drug monitoring, and disease activity in patients with inflammatory bowel disease: A retrospective cross-sectional study**
   Jelena Živić, Miloš Živić, Dušan Radojević, Vojislav Đukić, Mladen Maksić, Boško Nikolić, Nataša Zdravković



10. **Inflammatory cytokine profiles in patients with Crohn's disease in relation to periodontal manifestations**
    Miloš Živić, Jelena Živić, Dušan Radojević, Vojislav Đukić, Mladen Maksić, Boško Nikolić, Nataša Zdravković

11. **Association of platelet reactivity with histopathological changes in ulcerative colitis**
    Mladen Maksić, Dušan Radojević, Vojislav Đukić, Jelena Živić, Boško Nikolić, Saša Perić, Tijana Maksić, Mateja Zdravković, Zeljko Todorović, Miloš Živić, Nataša Zdravković

12. **Ulcerative Colitis Activity in the Context of Atherosclerosis: Associations Between Laboratory and Histopathological Indicators**
    Vojislav Đukić, Dušan Radojević, Mladen Maksić, Jelena Živić, Boško Nikolić, Tijana Maksić, Mateja Zdravković, Zeljko Todorović, Miloš Živić, Nataša Zdravković

13. **Extent of Ulcerative Colitis and Platelet Reactivity: Association of Disease Distribution with Laboratory Parameters**
    Mladen Maksić, Dušan Radojević, Vojislav Đukić, Jelena Živić, Boško Nikolić, Saša Perić, Tijana Maksić, Mateja Zdravković, Zeljko Todorović, Miloš Živić, Nataša Zdravković


14. **Association of histological features with natriuretic peptide levels in moderate-to-severe ulcerative colitis treated with azathioprine**
    Dušan Radojević, Mladen Maksić, Vojislav Đukić, Jelena Živić, Boško Nikolić, Mirjana Cvetković, Tijana Maksić, Mateja Zdravković, Zeljko Todorović, Miloš Živić, Nataša Zdravković

15. **Kožne promene tokom anti-TNF-α terapije kod pacijenata sa inflamatornim bolestima creva: iskustvo jednog centra**
    Aleksandar Topličanin, Saša Vuksanović, Jelena Spirić-Milovančević, Andreja Nikolić, Teodora Ivanović, Nikola Korać, Ivana Jovičić, Srđan Đuranović, Aleksandra Pavlović Marković, Aleksandra Sokić Milutinović

16. **Umor kao rezidualni simptom inflamatorne bolesti creva u remisiji: Postoje li razlike među naprednim terapijama?**
    Živko Jovičić, Renata Bek Pupovac, Nebojša Janjić, Olgica Latinović Bošnjak, Tatiana Jocić

17. **Procena funkcionalne onesposobljenosti pacijenata sa inflamatornom bolešću creva u remisiji IBD-diskom: Da li postoji razlika između anti-TNF terapije i vedolizumaba?**
    Renata Bek Pupovac, Živko Jovičić, Nebojša Janjić, Olgica Latinović Bošnjak, Tatiana Jocić

18. **Low-grade tubuloglandularni adenokarcinom kolona nastao na terenu Kron kolitisa: Dijagnostički izazov novoopisanog entiteta**
    Ivan Ilić, Jana Cvetković, Biljana Radovanović Dinić, Ilija Golubović



19. **Povezanost anemije i nutritivnog statusa kod dece obolele od inflamatornih bolesti creva**
Savina Marković, Mirjana Stojšić, Ognjen Ležakov, Milica Kovačević, Marko Rajković, Nina Brkić, Nikola Stojšić

20. **Long-Term Efficacy and Safety of Tulisokibart in Participants with Ulcerative Colitis: The Open-Label Extension of the Phase 2 ARTEMIS-UC Study**
Wen Zhou; Christopher Ma; Sami Hoque; Miles P. Sparrow; Jaclyn K. Anderson; Mark Yen; Bin Dong; Brian G. Feagan; Bruce E. Sands

21. **Efikasnost ustekinumaba u postizanju kliničke remisije kod pacijenata sa inflamatornim bolestima creva nakon neuspeha prethodne biološke terapije**
Teodora Ivanović, Saša Vuksanović, Jelena Spirić-Milovančević, Andreja Nikolić, Nikola Korać, Aleksandar Topličanin, Ivana Jovičić, Srđan Đuranović, Aleksandra Pavlović Marković, Aleksandra Sokić Milutinović

22. **Ishodi trudnoća kod pacijentkinja sa inflamatornim bolestima creva na biološkoj terapiji-iskustvo jednog centra**
N. Korać, A. Topličanin, J. Spirić Milovančević, S. Vuksanović, T. Ivanović, A. Nikolić, S. Zgradić, S. Đuranović, I. Jovičić, A. Pavlović Marković, A. Sokić-Milutinović

23. **Metabolički sindrom i težina ulceroznog kolitisa: kliničke i imunološke implikacije**
Irfan Ćorović, Bojana Simović Marković, Ivan Jovanović, Milena Jurišević, Aleksandar Đukić, Nataša Zdravković, Marina Jovanović

24. **Sarkopenijska i dinapenijska gojaznost kod bolesnika sa inflamatornim bolestima creva na biološkoj terapiji**
Jelena Spirić Milovančević, Saša Vuksanović, Aleksandar Topličanin, Teodora Ivanović, Nikola Korać, Andreja Nikolić, Srđan Đuranović, Ivana Jovičić, Aleksandra Pavlović Marković, Aleksandra Sokić-Milutinović


25. **Uticaj pola na rani biohemijski odgovor na vedolizumab kod bolesnika sa ulceroznim kolitisom**
S. Vuksanović, A. Topličanin, J. Spirić Milovančević, T. Ivanović, N. Korać, A. Nikolić, S. Đuranović, I. Jovičić, A. Pavlović Marković, A. Sokić-Milutinović

26. **Perzistencija biološke terapije kod inflamatornih bolesti creva u realnoj kliničkoj praksi: Uticaj klase leka i kombinovane terapije sa imunomodulatorima**
Nada Pekić, Tatiana Jocić, Olgica Latinović-Bošnjak, Nebojša Janjić, Željka Savić

27. **Management of refractory immune checkpoint inhibitors (ICI) colitis during ICI rechallenge in patients on vedolizumab maintenance**
Anđela Stanović



28. **Vedolizumab posle neuspeha anti-TNF terapije: petogodišnja perzistencija kohortna studija iz realne kliničke prakse**
    Nikola Stojšić, Olgica Latinović-Bošnjak, Tatiana Jocić, Mirjana Stojšić
29. **Povezanost indeksa telesne mase sa nivoima GLP-1 i GLP-2 kod pacijenata sa inflamatornim bolestima creva**
    Jelena Radlović, Danilo Vojvodić, Nemanja Rančić, Stanko Petrović
30. **"Window of opportunity" in IBD – Should we chase it? Results from a single-center cohort study**
    Aleksa Begović, Luka Jeremić, Denis Tarabar, Zoran Milenković, Dino Tarabar




IBD sestra danas – od dijagnoze do kvaliteta života IBD pacijenta

Subota, 7. novembar 2026.

09.00-09.20	Pozdravna reč Prof. dr Dino Tarabar, predsednik SIBDA
09.20-09.40	Uvodna reč – najava programa Žaklina Pajević, predsednica Udruženja gastroenterohepatoloških i endoskopskih medicinskih tehničara
	I sesija **Moderatori: Svetlana Rakićević, Žaklina Pajević**
09.40-10.00	Patofiziologija zapaljenskih bolesti creva Dr Zoran Milenković, KBC dr Dragiša Mišović
10.00-10.20	IBD sestra – nezamenljiv član multidisciplinarnog tima VSS Nataša Maksimović, UKC Vojvodina
10.20-10.40	Napredne terapije u IBD-u, šta IBD sestra mora da zna Jasmina Nikolić, UKC Kragujevac
10.40-11.00	Treat to Target, od terapijskih ciljeva do kliničke prakse, značaj IBD sestre na tom putu Dipl. med. sestra Svetlana Rakićević, KBC dr Dragiša Mišović
11.00-11.20	Edukacija pacijenata i unapređenje adherencije VSS Jovana Milošević, KBC Zvezdara
11.20-12.00	Diskusija
12.00-12.20	Kafe pauza
	II sesija **Moderatori: Svetlana Rakićević, Žaklina Pajević**
12.20-12.35	Sestrinska podrška i edukacija adolescenata sa IBD tokom tranzicije u adultnu gastroenterološku službu VSS Ivona Činčurak, Institut za zdravstvenu zaštitu dece i omladine Vojvodine, Novi Sad
12.35-12.50	Prikaz slučaja pacijenta obolelog od Mb Crohna MS Ivana Ilić, UKC Srbija
12.50-13.10	Kako davati biološku terapiju sa istorijom maligniteta MS Firdevsa Isaković, UKC Tuzla



13.10-13.30	Život sa zapaljenskim bolestima creva – kvalitet života izvan kontrole bolesti SSMS Tanja Sošić, KC Podgorica
13.35-14.00	Diskusija
14.00-15.00	Ručak
	III sesija **Moderatori: Žaklina Pajević, Snežana Manov**
15.00-15.15	Endoskopija kod IBD pacijenta počinje pre endoskopskog pregleda – značaj adekvatne pripreme VSS Jelena Marković, KBC dr Dragiša Mišović
15.15-15.30	Od dijagnoze do mukoznog zarastanja – šta medicinska sestra treba da zna o endoskopiji kod IBD pacijenta VMS Ivana Basara, KBC dr Dragiša Mišović
15.30-15.45	Kada hirurgija postaje deo lečenja IBD pacijenta – značaj medicinske sestre VSS Dragana Džinić, KBC dr Dragiša Mišović
15.45-16.00	Od operacione sale do kuće – postoperativna nega i edukacija IBD pacijenta i porodice VSS Gordana Petrović, KBC dr Dragiša Mišović
16.00-16.45	UKUKS – panel diskusija: Pogled iz ugla pacijenta Moderator: Olivera Ćulibrk Panelisti: Nada Brković, Srbija (UKUKS); Željko Gardlo, Hrvatska (Udruženje HUCUK); Mateja Saje, Slovenija (Društvo KVČB)
16.45-17.15	Diskusija
17.15-17.45	Izlazni test i zatvaranje sestrinskog skupa
20.30	Svečana večera



SPONZORI / SPONSORS

MEDICALINEA PHARM

abbvie

Takeda

Johnson&Johnson

Hemofarm STADA GRUPA

ewo pharma since 1959

Save health

FERRING PHARMACEUTICALS

OKTAL PHARMA

ADC

ADEXILIS

Milbourg doo

AbelaPharm

PONTUS

Pfizer

Goodwill

BAYER

